A. Malekniazi

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial

A. Marx, S. Muley, R. Conwit, 2019, The Lancet Neurology.

Eculizumab improves fatigue in refractory generalized myasthenia gravis

K. Patra, P. van Damme, M. Benatar, 2019, Quality of Life Research.

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.

G. L. Masson, W. Löscher, P. Vermersch, 2017, The Lancet. Neurology.

Evidence of multiple taxa within commercially available reference strains of Corynebacterium xerosis

R. Leonard, M. Coyle, A. Malekniazi, 1993, Journal of clinical microbiology.

Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study

P. van Damme, M. Benatar, F. Piehl, 2019, Journal of the Neurological Sciences.

Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

J. Statland, M. Pasnoor, J. Verschuuren, 2021, The Lancet Neurology.

Clinical, Biological and Pathological Characteristics of Breast Cancer Patients at the Taleghani University Hospital in Kermanshah, Iran

A. Ghavamzadeh, N. Amiri, V. Farnia, 2005 .

‘Minimal symptom expression’ in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab

P. van Damme, M. Benatar, F. Piehl, 2020, Journal of Neurology.